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eDITORIAL COMMENT
rimary Percutaneous Coronary
ntervention at Hospitals
ithout On-Site Cardiac Surgery
xpanding the Use of
echanical Reperfusion for
cute Myocardial Infarction*
ruce R. Brodie, MD, FACC
reensboro, North Carolina
echanical reperfusion was introduced as a reperfusion
trategy for ST-segment elevation acute myocardial infarc-
ion (AMI) in the mid- and late 1980s and offered advan-
ages over thrombolytic therapy in achieving higher infarct
rtery patency rates with less re-occlusion. With the publi-
ation of the Zwolle and PAMI trials in 1993 (1,2), which
ocumented superior outcomes with primary percutaneous
oronary intervention (PCI) over thrombolytic therapy,
rimary PCI became a legitimate competing reperfusion
trategy at interventional facilities with experienced opera-
ors. There are now over 23 randomized trials documenting
he superiority of mechanical reperfusion over thrombolytic
herapy (3), and primary PCI has become the preferred
eperfusion strategy when experienced operators can per-
orm it in a timely manner. However, the use of primary
CI has been limited owing to the lack of interventional
acilities at most hospitals and the reluctance of physicians
o transfer patients with AMI who present at community
ospitals to interventional facilities because of concerns
bout the deleterious effects of treatment delay on myocar-
ial salvage and clinical outcomes. This has stimulated new
trategies to provide primary PCI to patients presenting to
on-interventional hospitals.
See page 1943
In this issue of the Journal, Wharton et al. (4) present
ata from a prospective multi-center registry in high-risk
atients with AMI, presenting to hospitals with catheter-
zation facilities but no cardiac surgery on site (no-SOS),
ho were treated with primary PCI. Outcomes in this
egistry were compared with outcomes of patients enrolled
n the Air PAMI randomized trial who presented to
on-interventional hospitals, had identical high-risk inclu-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the LeBauer Cardiovascular Research Foundation, Moses Cone Heart andpascular Center, Greensboro, North Carolina.ion criteria, and were randomized to transfer to a tertiary
enter for primary PCI. Time to treatment (symptom onset
o balloon inflation) was 67 min shorter for patients treated
t no-SOS hospitals than for patients transferred to inter-
entional facilities in the Air PAMI trial, and outcomes at
0 days were similar between the two groups. Unadjusted
ne-year mortality was lower in the no-SOS group, but after
djusting for differences in baseline variables, there were no
ifferences in mortality. The need for emergency surgery for
ailed PCI was very low (0.4%), although surgical availabil-
ty was still important because 5% of patients required
ransfer for surgery when critical coronary anatomy was
ound at angiography. The investigators emphasized the
mportance of adhering to stringent guidelines to achieve
ptimal results, including the following: 1) experienced
nterventionalists who regularly perform elective interven-
ions at a surgical center; 2) an experienced catheterization
aboratory team available 24 hours a day, seven days a week;
) a well-equipped catheterization laboratory with digital
maging equipment and a full array of interventional equip-
ent; 4) formalized protocols for rapid transfer to a surgical
enter when necessary; and 5) rigorous, ongoing quality/
ssurance and outcomes monitoring.
This study is the largest multi-center registry of primary
CI performed at hospitals with interventional capabilities
ut without surgery on site. Although the study does not
rovide randomized data comparing outcomes with primary
CI at no-SOS hospitals with outcomes in patients trans-
erred to tertiary hospitals for primary PCI, the comparative
ata with similar patients transferred for primary PCI in the
ir PAMI trial put these outcomes into perspective and
rovide strong support for the use of primary PCI at centers
ithout on-site surgery.
The safety and efficacy of primary PCI for AMI at
o-SOS hospitals have also been supported by the results of
he Atlantic Cardiovascular Patient Outcomes Research
eam (C-PORT) trial and data from the National Registry
f Myocardial Infarction. The C-PORT trial (5) evaluated
rimary PCI at hospitals with catheterization laboratories
ut without cardiac surgery or elective PCI. Using skilled
perators who performed PCI at nearby tertiary centers, the
-PORT investigators documented superior outcomes with
rimary PCI versus lytic therapy. The National Registry of
yocardial Infarction investigators (6) evaluated outcomes
n 1,935 patients treated with primary PCI at 97 no-SOS
ospitals and compared them with outcomes in patients
reated at hospitals with on-site surgery and found similar
utcomes in both groups.
Thus, it appears clear from the data of Wharton et al. (4)
nd others that primary PCI can be performed safely and
ffectively at hospitals that do elective catheterization but do
ot have cardiac surgery on site, if rigorous guidelines are
ollowed. A more difficult question is whether this experi-
nce can be duplicated at other hospitals that perform
rimary PCI without on-site surgery. Some have argued
t
s
p
c
H
e
p
w
y
w
s
b
l
t
t
c
w
c
o
s
A
m
s
e
(
p
s
a
i
l
s
h
g
m
t
a
p
p
i
w
g
c
a
c
c
e
p
h
P
F
i
P
c
h
p
t
T
s
w
e
s
w
P
w
b
i
i
b
c
p
h
t
t
c
e
c
a
d
t
d
o
t
t
t
r
r
t
t
w
s
t
S
c
(
w
a
p
h
o
p
p
T
r
d
c
i
T
1952 Brodie JACC Vol. 43, No. 11, 2004
Editorial Comment June 2, 2004:1951–3hat the requirement for cardiac surgery on site acts as a
urrogate for an experienced team and comprehensive sup-
ort services, which are necessary to ensure optimal out-
omes. There remain a number of unanswered questions.
ow difficult will it be to find interventionalists with
xperience at tertiary hospitals to staff these no-SOS hos-
itals, and where will the technicians get their experience,
hen only as few as 36 interventions may be performed per
ear at these hospitals? Is it feasible to have all the catheters,
ires, balloons, and stents in stock and available for
ometimes-complex interventions when only a small num-
er of interventions are performed per year? Will these
ow-volume hospitals be able to adapt to rapidly changing
echnologies such as distal protection? And who will assume
he responsibility for monitoring quality/assurance and out-
omes data from these hospitals? These questions and more
ill need to be addressed as we embark on this new frontier.
The study by Wharton et al. is extremely relevant because
urrently there is great debate regarding the appropriateness
f performing primary PCI at hospitals without on-site
urgery. Current American College of Cardiology/
merican Heart Association guidelines permit the perfor-
ance of primary PCI at hospitals without on-site cardiac
urgical back-up if procedures can be performed by experi-
nced operators (75 procedures/year) in a timely fashion
90  30 min of arrival), if at least 36 primary PCI
rocedures are performed per year at the hospital, and if
tringent guidelines are in place similar to those described
bove (7). Primary PCI at no-SOS hospitals have a class IIb
ndication, which means that the usefulness and efficacy are
ess well established by current evidence and opinion. This
tudy documents that superb outcomes can be achieved at
ospitals that do not offer on-site cardiac surgery. Emer-
ency surgery for failed PCI is very infrequent and can be
anaged effectively with proper protocols for transfer to a
ertiary facility. Therefore, despite the questions posed
bove, I believe the data presented by Wharton et al.
rovide sufficient evidence to revise these guidelines to
rovide a class IIa indication (weight of evidence/opinion is
n favor of usefulness/efficacy) for primary PCI at hospitals
ith catheterization laboratories but without on-site sur-
ery. It will then be our responsibility as a cardiology
ommunity to ensure that these procedures are performed
ccording to the guidelines outlined above and that out-
omes are monitored.
The use of primary PCI at hospitals without on-site
ardiac surgery is part of a greater movement, that of
xpanding primary PCI to a larger segment of our AMI
opulation. Recently, the results of two randomized trials
ave added momentum to expanding the use of primary
CI. The large Danish Multicenter Randomized Study on
ibrinolytic Therapy versus Acute Coronary Angioplasty
n Acute Myocardial Infarction (DANAMI-2) and
RAGUE-2 trials (8,9) have documented superior out-
omes in patients with AMI transferred from community
ospitals to interventional facilities for primary PCI com- cared with local treatment with lytic therapy, despite addi-
ional treatment delays of 60 to 90 min in the PCI group.
his has spawned the concept of heart attack centers,
imilar to trauma centers, in which patients with AMI
ould be transferred directly to high-volume centers of
xcellence with mechanical reperfusion. In this “hub-and-
poke” model, all patients presenting at outlying hospitals
ould be transferred to interventional centers for primary
CI. Ideally, patients brought to the hospital by ambulance
ould be routed directly to the heart attack center, as has
een often done in Europe and is done with trauma patients
n this country. Unfortunately, this has not worked very well
n this country, because of the small proportion of patients
rought to the hospital by ambulance and the lack of
entralized emergency transport systems to facilitate this
rocess. Most patients present directly to the community
ospital (not by ambulance) and, unfortunately, hospitals in
his country have not yet been able to duplicate the rapid
riage and transport seen in the European trials. Despite
urrent limitations, the hub-and-spoke model may be an
ffective approach. Treatment delays do not appear as
ritical with primary PCI as with thrombolytic therapy (10)
nd, as the results of DANAMI-2 and PRAGUE-2 show,
o not appear to greatly compromise outcomes. An excep-
ion is the group of patients who present very early when
elays in treatment with primary PCI may compromise
utcomes. In PRAGUE-2, patients randomized at less than
hree hours had no mortality benefit with primary PCI over
hrombolytic therapy. In these patients “facilitated PCI,”
he use of pharmacologic reperfusion therapy followed by
apid transport for facilitated PCI, may allow for earlier
eperfusion with improved outcomes and may prove to be
he optimal approach. Facilitated PCI is currently being
ested in several randomized trials and, if effective, would
ork well with the hub-and-spoke model.
The National Registry of Myocardial Infarction has
hown modest trends for increased use of primary PCI over
he past decade, but in 2001 only 20% of patients with
T-segment elevation AMI were treated with primary PCI
ompared with 50% treated with thrombolytic therapy (11)
Fig. 1). The expanded use of primary PCI at hospitals
ithout on-site cardiac surgery and the development of
cute MI centers with protocols for rapid transport of
atients presenting at non-interventional hospitals will both
elp expand the use of primary PCI to a larger proportion of
ur AMI population. Currently, the hub-and-spoke ap-
roach appears to have a wider application, but in the future
rimary PCI at no-SOS hospitals may play a larger role.
he use of elective revascularization with PCI is increasing
apidly, whereas the use of coronary artery bypass grafting is
eclining. Rather than opening new surgery centers to
ompliment new PCI centers, it is likely that there will be
ncreasing pressure to “uncouple” cardiac surgery and PCI.
his would result in a large number of free-standing PCIenters performing elective PCI without on-site cardiac
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erforming primary PCI.
The differences in outcomes between mechanical reper-
usion strategies and pharmacologic reperfusion strategies
re not trivial. It should no longer be acceptable in most
atients to give only thrombolytic therapy when mechanical
eperfusion is available. And we, as a cardiology community,
hould vigorously promote making mechanical reperfusion
ore available. The performance of primary PCI at facilities
ith interventional capabilities but without on-site cardiac
urgery will help us toward this goal.
eprint requests and correspondence to: Dr. Bruce R. Brodie,
eBauer Cardiovascular Research Foundation, 313 Meadowbrook
errace, Greensboro, North Carolina 27408. E-mail: bbrodie@
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igure 1. Trends in the use of reperfusion therapy for ST-segment
levation acute myocardial infarction from the National Registry of
yocardial Infarction (11).EFERENCES
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